Elon Musk’s visionary project to embed microchips into human brains has faced a major hurdle as the US medical regulators rejected its clinical trials application over safety concerns. His Neuralink endeavor, which aims to help people suffering from blindness or paralysis, faced several risks that worried medical professionals about its safety. The regulators were worried that tiny electrodes could pose health hazards, impair cognitive function, or rupture blood vessels in the human brain. The Neuralink project uses AI technology in brain computer interfaces (BCI) to read brain activity by inserting tiny chips into the human skull.
The animal rights community has put pressure on Musk’s company as several monkeys, pigs, and sheep died during its experiments. In February, Neuralink revealed that it euthanized some of its animals during experiments due to device failures, infections or complications. Despite its setbacks, Musk’s management remains optimistic about future prospects of Neuralink. The firm’s plans to begin clinical trials this spring have faced delays, but are not altogether scrapped. The Synchron model, Neuralink’s main competitor, offers similar technologies that can be inserted into blood vessels for brain signals detection, and has already received approval for clinical trials. Nevertheless, setbacks are not uncommon in medical device companies, and Neuralink’s ambitious dream to build a brain-computer interface may still come to fruition.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
